Interesting, Reagan and Dulles may have been closed with nearly all flights cancelled Friday and Saturday. Flights from Davos were diverted to Florida. TV showed local runways still being cleared this morning, and DC mayor said an announcement would be made later today as to when DC streets would be open to traffic.
Above may be pertinent to 1/25/2016 opening of convention.
Funny Youtube by Immunotherapy-World-Conf./WashDC re: The Storm.
We were Ready for a Nice Sunny Meeting in Washington. ...AND THEN… We're right in the middle of The Blizzard of 2016… BUT WHY LET A LITTLE SNOW SPOIL THE MEETING? - - - - - - Thank You to Everyone Who Made It. - - - - - - And, See You Next Year in... MIAMI !! SEE YOU NEXT YEAR!!! . . = = = = = = = = = = = = = Jan25-27 2016: “Phacilitate's Immunotherapy World Conf.”, WashDC http://www.immunotherapyforum.com “After years of posting impressive clinical results and pushing analyst projections to greater and greater heights, immuno-oncology has solidified its status as the most exciting development in cancer treatment for a long time. Now that checkpoint inhibitors have uncloaked cancer cells, drug developers are investigating dozens of immune drug cocktails (everything from CAR-T to antibodies, vaccines and other cellular therapies) to find well-tolerated treatments which could become the first-in-line to fight cancer in patients. We have all heard of the stunning breakthroughs at ASCO'15. BMS’ Opdivo + Yervoy study which lead to a 58% shrinkage of tumors and a PFS superiority of 8.6mos. against monotherapies in patients with melanoma. AstraZeneca’s own PD-L1 (MEDI4736/durvalumab)[see 10-15-15 AZN/PPHM Collab. Expansion: http://tinyurl.com/q79bkam ] and CTLA-4 (Tremelimumab) inhibitor combination, which demonstrated an ORR of 27% in the treatment of NSCLC… On Jan25-27 2016, 750 deal-makers will gather in the Grand Hyatt Hotel to discuss the direction, future and value of cell, gene and immunotherapy portfolios.” 1-24-16 Agenda Update due to storm – everything moved back ~30mins: http://www.immunotherapyforum.com/files/new_immunotherapy_agenda.pdf --------- Jan25(Day1): Focus Session1, “Cellular Cancer Immunotherapy: Optimizing Combination Therapy Development Strategy” 3:15pm: Chair's intro, David Lebwohl, NOVARTIS 3:20: Michael Hanna, VACCINOGEN, “The Provocative Issues of Tumor Heterogeneity on Active Specific Immunotherapy...” 3:35: Laura Benjamin, ELI LILLY, “Challenges/Opportunities for Translational Science to Guide Angiogenesis/Combos w/Immunotherapy” 3:50: Taylor Schreiber, HEAT BIOLOGICS, “Dual-Acting Immunotherapy with ComPACT - Vaccination & Co-Stimulation...” ------- 1-25-16 4:05-4:20pm: Jeff T. Hutchins (PEREGRINE'S VP/PreClinRes), “Combination Immunotherapies - Opening the Gate: Increasing Tumor Infiltrating Activated T-cells to Optimize and Expand the Benefits of Immune Checkpoint Therapies” * Analyzing complimentary mechanisms in therapeutics and building solid partnerships * Utilizing scientifically-driven data to build a product value story * Demonstrating how a product fits within a treatment in combination(s) and against competitive therapies ------- 4:20pm: Robert Preti, PCT(CALADRIUS), “What Does Commercialization Look Like?” - - - - - - - - - - - - - - - -From PPHM's 1-20-16 PR: http://tinyurl.com/z65avfw “In his talk, Dr. Hutchins will discuss strategies for expanding the therapeutic benefit seen with immuno-oncology monotherapies to a broader range of patients using combination treatment approaches. Specifically, he will highlight the strategy of leveraging treatments capable of increasing the number & activity of T-cells in the tumor microenvironment to optimize the therapeutic benefit of immune checkpoint inhibitors such as anti-PD-1/anti-PDL-1 agents. Dr. Hutchins will draw on the company's experience in working with preclinical equivalents of bavituximab, Peregrine's lead investigational phosphatidylserine (PS)-targeting immunotherapy candidate. PS-targeting antibodies have been shown to shift the immunosuppressive functions of immune cells in tumors, resulting in anti-tumor immune responses. Peregrine has generated results from multiple preclinical & clinical-translational studies demonstrating enhanced anti-tumor activity and immune activation when combining equivalent PS-targeting antibodies with conventional chemotherapy or checkpoint inhibitors such as anti-PD-1 agents.”
Interesting CJ, if Avid Bioservices makes royalty payments from Oncologie and some of that is based upon collaborations with TPIV where Ken Dart is highly invested....I wonder why all sorts of IP asset transfers were initiated
That is of course....if TPIV is linked to any PS Targeting IP
Dr Laura Benjamin was there with Peregrine rep
Dr Keith Knutson and Edith Perez was there ...TPIV ties
Market Data 
Markets 
AI
